{
    "clinical_study": {
        "@rank": "42035", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess safety and the inhibition of restenosis of the CVI\n      Paclitaxel-coated PTA Balloon Catheter in the treatment of de-novo occluded/stenotic or\n      reoccluded/restenotic superficial femoral (SFA) or popliteal arteries.\n\n      The primary endpoint for this analysis is late lumen loss at six (6) months."
        }, 
        "brief_title": "CVI Drug Coated Balloon First In Human Trial", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Arterial Disease", 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Prospective, controlled, multi-center, open, single arm study\n\n      Main cohort: 50; pre-specified treatment group: 30. Total patients: 80"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with symptomatic leg ischemia, requiring treatment of SFA or popliteal (P1\n             segment) artery\n\n          -  De novo or restenotic lesion(s) >70% within the SFA and popliteal arteries in a\n             single limb which are \u22653 cm and \u226415 cm in cumulative total length (by visual\n             estimation).\n\n          -  Target vessel reference diameter \u22653 mm and \u22647 mm (by visual estimation).\n\n          -  Rutherford classification of 2, 3 or 4\n\n        Exclusion Criteria:\n\n          -  Lesion length is <3 cm or >15 cm or there is no normal proximal arterial segment in\n             which duplex ultrasound velocity ratios can be measured.\n\n          -  Outflow arteries (distal popliteal, anterior or posterior tibial or peroneal\n             arteries) with significant lesions (\u2265 50% stenosis) may not be treated during the\n             same procedure.\n\n          -  Treatment of the contralateral limb during the same procedure or within 30 days of\n             the study procedure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110524", 
            "org_study_id": "TP1027"
        }, 
        "intervention": {
            "intervention_name": "Percutaneous Transluminal Angioplasty", 
            "intervention_type": "Device", 
            "other_name": [
                "CVI Paclitaxel-coated, Percutaneous Transluminal Angioplasty (PTA) Balloon", 
                "Catheter"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Peripheral Arterial Disease", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "13347"
                }, 
                "name": "Jewish Hospital Berlin"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective, Controlled, Multi-Center, Open, Single Arm Study for the Treatment of Subjects Presenting De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using a Paclitaxel-Coated Percutaneous Angioplasty Catheter", 
        "overall_official": {
            "affiliation": "Jewish Hospital Berlin", 
            "last_name": "Henrik Schr\u00f6der, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "difference between minimum lumen diameter after intervention and follow up.", 
            "measure": "Primary endpoint: Angiographic late lumen loss", 
            "safety_issue": "Yes", 
            "time_frame": "6Month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "composite rate of cardiovascular death, index limb amputation and ischemia driven target lesion revascularization (TLR).", 
            "measure": "Secondary safety endpoint: Major Adverse Event (MAE) rate", 
            "safety_issue": "No", 
            "time_frame": "6Months"
        }, 
        "source": "Covidien", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Covidien", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}